Background: Activating RET alterations drive oncogenic signaling in lung, thyroid, and other solid tumors.Until recently, only two RET tyrosine kinase inhibitor (TKI), BLU-667 and LOXO-292, had ...

Background: LIV-1, also known as SLC39A6 or ZIP6, is a transmembrane protein belonging to the zinc transporter family. LIV-1 is a promising target for antibody-drug conjugate (ADC) therapy due to its ...

Abstract. MTAP deletions occur in 10-15% of all human cancers, providing one of the largest precision oncology patient populations. MTA-cooperative PRMT5 inhibitors leverage the well-characterized ...

Cancer Res (2024) 84 (7_Supplement): CT009. Background: Treatment (tx) for LA SCCHN includes a combination of surgery, radiation and/or chemotherapy followed by monitoring for local recurrence/distant ...

Spencer Mirabile-Brightman, Bjoern Peters, Himangshu Sonowal, Zachary Berman, Zev Wainberg, Aaron Miller, Karen Messer, Jiayu Chen, Yago Pico de Coana, Peter Ellmark, Stephen Schoenberger, Rebekah R.

Tertiary lymphoid structures (TLS) are organized immune cell aggregates that assemble within tumors and function as local antitumor immune hubs. Although TLSs have emerged as promising biomarkers of ...

Background: SHR-A1921 is a novel ADC composed of a humanized anti-trophoblast cell-surface antigen 2 (TROP-2) IgG1 monoclonal antibody attached to a DNA topoisomerase I inhibitor via a ...

Cancer Immunol Res (2026) 14 (2_Supplement): B053. Accurate PK/PD and exploratory cytometry is central to evaluating mechanism, response, biomarkers, and safety in immunotherapy trials. Live-blood ...

Cancer Res (2025) 85 (8_Supplement_2): CT221. Patients with stage II colon cancer not classified as high risk (pT4 microsatellite stable) do not receive adjuvant chemotherapy (ACT) according to Dutch ...

Cancer Res (2023) 83 (8_Supplement): LB078. Sarcomas are a broad group of soft tissue and bone cancers that can be difficult to treat leading to a high mortality rate. Sarcomas comprise two broad ...

Cancer Discov (2026) 16 (7): OF1.

Cancer Discov (2026) 16 (7): OF1.